IE60490B1 - Freeze-Dried Pharmaceutical Compositions of Phenylquinoline carboxylic acids - Google Patents
Freeze-Dried Pharmaceutical Compositions of Phenylquinoline carboxylic acidsInfo
- Publication number
- IE60490B1 IE60490B1 IE229087A IE229087A IE60490B1 IE 60490 B1 IE60490 B1 IE 60490B1 IE 229087 A IE229087 A IE 229087A IE 229087 A IE229087 A IE 229087A IE 60490 B1 IE60490 B1 IE 60490B1
- Authority
- IE
- Ireland
- Prior art keywords
- salt
- sodium
- acid
- freeze
- fluoro
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- JIPUGCBCIYYRSB-UHFFFAOYSA-N 3-phenylquinoline-2-carboxylic acid Chemical group OC(=O)C1=NC2=CC=CC=C2C=C1C1=CC=CC=C1 JIPUGCBCIYYRSB-UHFFFAOYSA-N 0.000 title claims abstract description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 26
- 239000004471 Glycine Substances 0.000 claims abstract description 14
- 239000003833 bile salt Substances 0.000 claims abstract description 14
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims abstract description 12
- 159000000000 sodium salts Chemical class 0.000 claims abstract description 11
- 230000006641 stabilisation Effects 0.000 claims abstract description 10
- 239000000872 buffer Substances 0.000 claims abstract description 9
- 238000011105 stabilization Methods 0.000 claims abstract description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 12
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- CBEBHNPCZSDEAB-UHFFFAOYSA-N 2-(4h-quinolin-1-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1N1C2=CC=CC=C2CC=C1 CBEBHNPCZSDEAB-UHFFFAOYSA-N 0.000 claims description 5
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 3
- 239000011363 dried mixture Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000003182 parenteral nutrition solution Substances 0.000 claims description 3
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 2
- 229960003964 deoxycholic acid Drugs 0.000 claims description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims 1
- ALBQBKQVMVZCOP-UHFFFAOYSA-N 5-chloro-3-methyl-2-(4-phenylphenyl)quinoline-4-carboxylic acid Chemical compound N1=C2C=CC=C(Cl)C2=C(C(O)=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1 ALBQBKQVMVZCOP-UHFFFAOYSA-N 0.000 claims 1
- 239000004380 Cholic acid Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 229960002471 cholic acid Drugs 0.000 claims 1
- 235000019416 cholic acid Nutrition 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 17
- 230000000259 anti-tumor effect Effects 0.000 abstract description 6
- 239000007972 injectable composition Substances 0.000 abstract description 3
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 27
- 239000003814 drug Substances 0.000 description 20
- 229940079593 drug Drugs 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000002904 solvent Substances 0.000 description 15
- 150000007513 acids Chemical class 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 229940093761 bile salts Drugs 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000010668 complexation reaction Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- -1 prostaglandin E group compound Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- KWVPFECTOKLOBL-KTKRTIGZSA-N 2-[(z)-octadec-9-enoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCO KWVPFECTOKLOBL-KTKRTIGZSA-N 0.000 description 1
- FUKHTUIKAKDTBB-UHFFFAOYSA-N 2-chloro-3-methylquinoline-4-carboxylic acid Chemical compound C1=CC=CC2=C(C(O)=O)C(C)=C(Cl)N=C21 FUKHTUIKAKDTBB-UHFFFAOYSA-N 0.000 description 1
- OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000008364 bulk solution Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229960002997 dehydrocholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-M deoxycholate Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-M 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940099347 glycocholic acid Drugs 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90125486A | 1986-08-28 | 1986-08-28 | |
| US07/060,203 US4889862A (en) | 1986-08-28 | 1987-06-10 | Freeze-dried pharmaceutical compositions of phenylquinoline carboxylic acids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE872290L IE872290L (en) | 1988-02-28 |
| IE60490B1 true IE60490B1 (en) | 1994-07-27 |
Family
ID=26739681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE229087A IE60490B1 (en) | 1986-08-28 | 1987-08-27 | Freeze-Dried Pharmaceutical Compositions of Phenylquinoline carboxylic acids |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4889862A (enExample) |
| EP (1) | EP0261426B1 (enExample) |
| JP (1) | JP2629005B2 (enExample) |
| KR (1) | KR950006218B1 (enExample) |
| AU (1) | AU602715B2 (enExample) |
| CA (1) | CA1312824C (enExample) |
| DE (1) | DE3782480T2 (enExample) |
| DK (1) | DK168655B1 (enExample) |
| ES (1) | ES2052530T3 (enExample) |
| FI (1) | FI90824C (enExample) |
| GR (1) | GR3006608T3 (enExample) |
| HU (1) | HU199289B (enExample) |
| IE (1) | IE60490B1 (enExample) |
| IL (1) | IL83662A (enExample) |
| NO (1) | NO873626L (enExample) |
| NZ (1) | NZ221574A (enExample) |
| PT (1) | PT85612B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4861783A (en) * | 1988-04-26 | 1989-08-29 | E. I. Du Pont De Nemours And Company | 4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases |
| HU206975B (en) * | 1991-03-14 | 1993-03-01 | Reanal Finomvegyszergyar | Process for producing granulation and veterinary composition comprising water-soluble flumequine complex |
| US6417167B1 (en) | 1997-02-05 | 2002-07-09 | Kirin Beer Kabushiki Kaisha | Lyophilized compositions containing shingoglycolipid and process for preparing them |
| AU739673B2 (en) * | 1997-02-05 | 2001-10-18 | Kirin Pharma Kabushiki Kaisha | Lyophilized compositions containing sphingoglycolipid and process for preparing them |
| TWI232102B (en) * | 2001-07-17 | 2005-05-11 | Shionogi & Co | A pharmaceutical formulation for injection |
| US20060008529A1 (en) * | 2004-07-12 | 2006-01-12 | Meyerhoff Mark E | Use of additive sites to control nitric oxide release from nitric oxide donors contained within polymers |
| WO2007005758A2 (en) * | 2005-06-30 | 2007-01-11 | Mc3, Inc. | Methods , compositions and devices for promoting angiogenesis |
| CN101378792A (zh) * | 2005-12-02 | 2009-03-04 | 密执安大学评议会 | 聚合物组合物、涂层和装置及其制备和使用方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US468299A (en) * | 1892-02-02 | John atkinson | ||
| DE433646C (de) * | 1923-09-15 | 1926-09-09 | Chem Fab Vorm E Schering | Verfahren zur Herstellung in Wasser leicht loeslicher Derivate von Carbonsaeuren derChinolin- und Pyridinreihe |
| US3681495A (en) * | 1969-08-25 | 1972-08-01 | American Home Prod | Freeze dried echothiophate iodide compositions |
| JPS5071816A (enExample) * | 1973-11-02 | 1975-06-14 | ||
| US4036954A (en) * | 1973-11-02 | 1977-07-19 | Yamanouchi Pharmaceutical Co., Ltd. | Stable prostaglandin E group-containing formulation |
| AT356278B (de) * | 1976-07-12 | 1980-04-25 | Hoffmann La Roche | Verfahren zur herstellung von injektions- loesungen |
| JPS5976017A (ja) * | 1983-01-20 | 1984-04-28 | Yamanouchi Pharmaceut Co Ltd | 安定なプロスタグランジンｅ類製剤の製法 |
| US4680299A (en) * | 1984-04-30 | 1987-07-14 | E.I. Du Pont De Nemours And Company | 2-phenyl-4-quinolinecarboxylic acids and pharmaceutical compositions thereof |
| DE3483704D1 (de) * | 1983-07-22 | 1991-01-17 | Du Pont | Phenylchinolinsaeure und derivate als antitumormittel. |
| DE3329952A1 (de) * | 1983-08-19 | 1985-02-28 | Behringwerke Ag, 3550 Marburg | Verfahren zur verringerung einer truebung in kontrollseren |
| EP0179583A1 (en) * | 1984-10-04 | 1986-04-30 | Merck & Co. Inc. | A system for enhancing the water dissolution rate and solubility of poorly soluble drugs |
-
1987
- 1987-06-10 US US07/060,203 patent/US4889862A/en not_active Expired - Lifetime
- 1987-08-18 CA CA000544796A patent/CA1312824C/en not_active Expired - Fee Related
- 1987-08-26 ES ES87112367T patent/ES2052530T3/es not_active Expired - Lifetime
- 1987-08-26 EP EP87112367A patent/EP0261426B1/en not_active Expired - Lifetime
- 1987-08-26 NZ NZ221574A patent/NZ221574A/xx unknown
- 1987-08-26 DE DE8787112367T patent/DE3782480T2/de not_active Expired - Fee Related
- 1987-08-26 FI FI873701A patent/FI90824C/fi not_active IP Right Cessation
- 1987-08-27 KR KR1019870009364A patent/KR950006218B1/ko not_active Expired - Fee Related
- 1987-08-27 HU HU873780A patent/HU199289B/hu not_active IP Right Cessation
- 1987-08-27 PT PT85612A patent/PT85612B/pt not_active IP Right Cessation
- 1987-08-27 IE IE229087A patent/IE60490B1/en not_active IP Right Cessation
- 1987-08-27 AU AU77622/87A patent/AU602715B2/en not_active Ceased
- 1987-08-27 JP JP62211503A patent/JP2629005B2/ja not_active Expired - Lifetime
- 1987-08-27 DK DK447887A patent/DK168655B1/da not_active IP Right Cessation
- 1987-08-27 IL IL83662A patent/IL83662A/xx unknown
- 1987-08-27 NO NO873626A patent/NO873626L/no unknown
-
1992
- 1992-12-21 GR GR920403016T patent/GR3006608T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO873626D0 (no) | 1987-08-27 |
| KR950006218B1 (ko) | 1995-06-12 |
| FI873701L (fi) | 1988-02-29 |
| CA1312824C (en) | 1993-01-19 |
| KR880002507A (ko) | 1988-05-09 |
| AU602715B2 (en) | 1990-10-25 |
| DE3782480T2 (de) | 1993-04-08 |
| EP0261426A1 (en) | 1988-03-30 |
| AU7762287A (en) | 1988-03-03 |
| IE872290L (en) | 1988-02-28 |
| EP0261426B1 (en) | 1992-11-04 |
| DK168655B1 (da) | 1994-05-16 |
| NO873626L (no) | 1988-02-29 |
| PT85612B (pt) | 1990-05-31 |
| HU199289B (en) | 1990-02-28 |
| FI873701A0 (fi) | 1987-08-26 |
| NZ221574A (en) | 1989-11-28 |
| US4889862A (en) | 1989-12-26 |
| IL83662A0 (en) | 1988-01-31 |
| FI90824C (fi) | 1994-04-11 |
| ES2052530T3 (es) | 1994-07-16 |
| GR3006608T3 (enExample) | 1993-06-30 |
| JP2629005B2 (ja) | 1997-07-09 |
| DE3782480D1 (de) | 1992-12-10 |
| IL83662A (en) | 1991-09-16 |
| DK447887D0 (da) | 1987-08-27 |
| PT85612A (en) | 1987-09-01 |
| JPS63115816A (ja) | 1988-05-20 |
| FI90824B (fi) | 1993-12-31 |
| HUT45398A (en) | 1988-07-28 |
| DK447887A (da) | 1988-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4158707A (en) | Parenteral preparations | |
| DE69625200T2 (de) | Arzneimittel enthaltend lamotrigin | |
| EP0261426B1 (en) | Freeze-dried pharmaceutical compositions of phenylquinoline carboxylic acids | |
| AU2011304917B2 (en) | 5alpha-androstane (alkyl)-3beta,5,6beta-triol injection and preparation method therefor | |
| KR970000507B1 (ko) | 안정된 안트라사이클린 제제 | |
| US20150216928A1 (en) | Daptomycin injectable formulation | |
| CA2480425A1 (en) | Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation | |
| US4360523A (en) | Pharmaceutical formulations of 4'-(9-acridinylamino)-methanesulfon-m-anisidide | |
| IE63156B1 (en) | Dry substances and stable suspensions | |
| WO2022179490A1 (en) | Pharmaceutical compositions and preparation methods thereof | |
| DE69500490T2 (de) | Glattmuskelrelaxierende Arzneizubereitungen | |
| US5955456A (en) | Injectable pharmaceutical composition comprising ursodesoxycholic acid or tauroursodesoxycholic acid, a strong base and tromethamol | |
| CZ252897A3 (cs) | Farmaceutický prostředek | |
| EP2668952B1 (en) | Aqueous formulations of bisphosphonates, vitamin D and benzyl alcohol suitable for subcutaneous or intramuscular use | |
| DE3853079T2 (de) | Liposome hoher stabilität und verfahren zur herstellung und verwendung. | |
| JP2003528134A (ja) | 白血球産生の刺激用および腫瘍および原虫症の治療用およびダニ症、節足動物媒介感染の治療用医薬組成物およびその製法 | |
| EA003936B1 (ru) | Препараты эстрамустинфосфата и сульфоалкиловых эфиров циклодекстринов для парентерального применения | |
| RU1837878C (ru) | Способ получени противоопухолевого средства на основе производного хинолинкарбоновой кислоты | |
| JP3956654B2 (ja) | Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物含有溶液および製剤 | |
| AU6280900A (en) | Formulations for parenteral use of estramustine phosphate and albumin | |
| US4425348A (en) | Antitumor compositions | |
| EA005308B1 (ru) | Препараты эстрамустинфосфата для парентерального применения | |
| EP4134083A1 (en) | Pharmaceutical compositions of bortezomib | |
| AU2006235847C1 (en) | Lyophilized pantoprazole preparation | |
| BE845795A (nl) | Werkwijze ter bereiding van stabiele preparaten van wateroplosbare zouten van dehydro-epiandrosteronsulfaat voor parenterale toediening |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed |